Home > Research > Publications & Outputs > Quantifiable mRNA transcripts for tamoxifen-met...

Research

Associated organisational unit

Links

Text available via DOI:

Keywords

View graph of relations

Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium. / Singh, Maneesh N.; Stringfellow, Helen F.; Walsh, Michael J. et al.
In: Toxicology, Vol. 249, No. 1, 10.07.2008, p. 85-90.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Singh, MN, Stringfellow, HF, Walsh, MJ, Ashton, KM, Paraskevaidis, E, Abdo, KR, Martin-Hirsch, PL, Phillips, DH & Martin, FL 2008, 'Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium.', Toxicology, vol. 249, no. 1, pp. 85-90. https://doi.org/10.1016/j.tox.2008.04.009

APA

Singh, M. N., Stringfellow, H. F., Walsh, M. J., Ashton, K. M., Paraskevaidis, E., Abdo, K. R., Martin-Hirsch, P. L., Phillips, D. H., & Martin, F. L. (2008). Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium. Toxicology, 249(1), 85-90. https://doi.org/10.1016/j.tox.2008.04.009

Vancouver

Singh MN, Stringfellow HF, Walsh MJ, Ashton KM, Paraskevaidis E, Abdo KR et al. Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium. Toxicology. 2008 Jul 10;249(1):85-90. doi: 10.1016/j.tox.2008.04.009

Author

Singh, Maneesh N. ; Stringfellow, Helen F. ; Walsh, Michael J. et al. / Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium. In: Toxicology. 2008 ; Vol. 249, No. 1. pp. 85-90.

Bibtex

@article{24c13c101e2b46359b30761be1b980e5,
title = "Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium.",
abstract = "Tamoxifen has been used in the management of receptor-positive breast cancer for >20 years. Usage confers an elevated risk of developing endometrial carcinoma. Its mechanism of carcinogenicity remains unresolved with controversy as to whether or not this is mediated through a genotoxic mechanism. Usage is not only associated with an elevated occurrence of endometrioid endometrial carcinoma, but also type 2 and mixed epithelial-stromal tumours (MESTs) that have a poorer prognosis. Following hysterectomy, endometrial tissues (n = 18) classified as benign (n = 6), non-tamoxifen-associated carcinoma (n = 6) and tamoxifen-associated carcinoma (n = 6) were obtained; quantitative gene expression was performed. Employing real-time RT-PCR, the relative gene expressions of phase I/II metabolic enzymes CYP1A2, CYP1B1 and CYP3A4, cathechol-O-methyltransferase (COMT) and SULT2A1 were ascertained. Measurable mRNA transcripts, especially for those genes associated with tamoxifen bioactivation, were quantifiable in all the tissues examined. Whether this is evidence that generation of genotoxic tamoxifen metabolites may occur in human endometrial tissue remains to be ascertained.",
keywords = "CYP3A4, Endometrial carcinoma, Genotoxic, Selective oestrogen receptor modulator, SULT2A1, Tamoxifen",
author = "Singh, {Maneesh N.} and Stringfellow, {Helen F.} and Walsh, {Michael J.} and Ashton, {Kate M.} and Evangelos Paraskevaidis and Abdo, {Khalil R.} and Martin-Hirsch, {Pierre L.} and Phillips, {David H.} and Martin, {Frank L.}",
year = "2008",
month = jul,
day = "10",
doi = "10.1016/j.tox.2008.04.009",
language = "English",
volume = "249",
pages = "85--90",
journal = "Toxicology",
issn = "0300-483X",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium.

AU - Singh, Maneesh N.

AU - Stringfellow, Helen F.

AU - Walsh, Michael J.

AU - Ashton, Kate M.

AU - Paraskevaidis, Evangelos

AU - Abdo, Khalil R.

AU - Martin-Hirsch, Pierre L.

AU - Phillips, David H.

AU - Martin, Frank L.

PY - 2008/7/10

Y1 - 2008/7/10

N2 - Tamoxifen has been used in the management of receptor-positive breast cancer for >20 years. Usage confers an elevated risk of developing endometrial carcinoma. Its mechanism of carcinogenicity remains unresolved with controversy as to whether or not this is mediated through a genotoxic mechanism. Usage is not only associated with an elevated occurrence of endometrioid endometrial carcinoma, but also type 2 and mixed epithelial-stromal tumours (MESTs) that have a poorer prognosis. Following hysterectomy, endometrial tissues (n = 18) classified as benign (n = 6), non-tamoxifen-associated carcinoma (n = 6) and tamoxifen-associated carcinoma (n = 6) were obtained; quantitative gene expression was performed. Employing real-time RT-PCR, the relative gene expressions of phase I/II metabolic enzymes CYP1A2, CYP1B1 and CYP3A4, cathechol-O-methyltransferase (COMT) and SULT2A1 were ascertained. Measurable mRNA transcripts, especially for those genes associated with tamoxifen bioactivation, were quantifiable in all the tissues examined. Whether this is evidence that generation of genotoxic tamoxifen metabolites may occur in human endometrial tissue remains to be ascertained.

AB - Tamoxifen has been used in the management of receptor-positive breast cancer for >20 years. Usage confers an elevated risk of developing endometrial carcinoma. Its mechanism of carcinogenicity remains unresolved with controversy as to whether or not this is mediated through a genotoxic mechanism. Usage is not only associated with an elevated occurrence of endometrioid endometrial carcinoma, but also type 2 and mixed epithelial-stromal tumours (MESTs) that have a poorer prognosis. Following hysterectomy, endometrial tissues (n = 18) classified as benign (n = 6), non-tamoxifen-associated carcinoma (n = 6) and tamoxifen-associated carcinoma (n = 6) were obtained; quantitative gene expression was performed. Employing real-time RT-PCR, the relative gene expressions of phase I/II metabolic enzymes CYP1A2, CYP1B1 and CYP3A4, cathechol-O-methyltransferase (COMT) and SULT2A1 were ascertained. Measurable mRNA transcripts, especially for those genes associated with tamoxifen bioactivation, were quantifiable in all the tissues examined. Whether this is evidence that generation of genotoxic tamoxifen metabolites may occur in human endometrial tissue remains to be ascertained.

KW - CYP3A4

KW - Endometrial carcinoma

KW - Genotoxic

KW - Selective oestrogen receptor modulator

KW - SULT2A1

KW - Tamoxifen

U2 - 10.1016/j.tox.2008.04.009

DO - 10.1016/j.tox.2008.04.009

M3 - Journal article

VL - 249

SP - 85

EP - 90

JO - Toxicology

JF - Toxicology

SN - 0300-483X

IS - 1

ER -